The Decision Resources Pharmaview Competitive Assessment

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser

Decision Resources Pharmaview Competitive Assessment

News from ASCO: The Ongoing Push to Move Away From a ‘One Drug Treats All’ Approach in Cancer Treatment

— A Pharmaview Competitive Assessment from Decision Resources

You are invited to attend the Decision Resources Pharmaview competitive assessment entitled News from ASCO: The Ongoing Push to Move Away From a ‘One Drug Treats All’ Approach in Cancer Treatment.

Clinical trial data presented earlier this month at the American Society of Clinical Oncology (ASCO) annual meeting continues to support physicians’ and researchers’ ongoing push for a move away from a ‘one drug treats all’ therapeutic approach towards individualized treatments for specific subsets of cancer patients. This session will investigate the competitive implications of the changing sentiment and will provide a broad overview of the hot topics, themes and clinical trial results presented at the 2010 ASCO meeting.

This presentation will also provide a schedule of exclusive upcoming Pharmacor analyst calls that will highlight news from the ASCO conference regarding several oncology indications including ovarian cancer, multiple myeloma and gastric cancer.

This 20-minute session, presented by Analyst Kiran Meekings, Ph.D., will answer the following questions:

Does c-Met therapy hold blockbuster potential for the treatment of non-small-cell lung cancer? Which companies are likely to succeed in the developmental race for c-Met inhibitors?
How do we see the ovarian cancer competitive environment changing in light of data released at ASCO?
How will data presented at ASCO position Amgen’s Prolia compared to Novartis’ Zometa? And what is the latest sentiment regarding the therapeutic potential of bone-resorption inhibitors?
Are we envisaging further upside for Celgene’s Revlimid and Roche’s Rituxan following the positive maintenance data presented at ASCO?

Dr. Meekings will conduct a live Q & A session after the presentation.

Registration

News from ASCO: The Ongoing Push to Move Away From a ‘One Drug Treats All’ Approach in Cancer Treatment

June 22, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To register, click here to reach our WebEx Event Center page, then click ‘Register” for this event.

*Please register by 8 a.m. U.S. Eastern Time on June 22 in order to attend the event.

For more information please contact Jackie Jordan at 781-296-2662 or jjordan@dresources.com

Event Details

Date & Time
Tuesday, June 22, 2010
10 a.m. ET, 4 p.m. CET

Presentation: 20 minutes

Q & A: 10 minutes

About the Speaker

Kiran Meekings, Ph.D., a senior analyst within the Pharmaview team at Decision Resources, specializes in providing qualitative and quantitative analysis of major pipeline and marketed oncology products within the global pharmaceutical market. Before joining Decision Resources, she was a pharmaceutical equity research analyst at Merrill Lynch and completed her doctorate on oncogenic viral infections at Imperial College London. Prior to obtaining her Ph.D., she earned a first-class honors degree in Natural Sciences from the University of Cambridge.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.